Recently, genetically targeted cancer therapies have been a topic of great interest. Synthetic
lethality provides a new approach for the treatment of mutated genes that were previously …

The retinoblastoma (RB) tumor suppressor is known as a master regulator of the cell cycle.
RB is mutated or functionally inactivated in the majority of human cancers. This …

Because traditional treatment strategies for advanced gastrointestinal (GI) cancers often
have a limited therapeutic effect, immunotherapy could be a viable approach for the therapy …

ARID1A is a core DNA-binding subunit of the BAF chromatin remodeling complex, and is
lost in up to 7% of all cancers. The frequency of ARID1A loss increases in certain cancer …

Abstract Polybromo-1 (PBRM1) loss of function mutations are present in a fraction of biliary
tract cancers (BTCs). PBRM1, a subunit of the PBAF chromatin-remodeling complex, is …

ARID1A, a component of the SWI/SNF chromatin remodeling complex, is a tumor suppressor
with a high frequency of inactivating mutations in many cancers. Therefore, ARID1A …

Simple Summary Translation of the molecular characterization of endometrial cancer into
the clinical practice is emerging as a challenge. This study investigates the feasibility and …

The establishment and maintenance of genome packaging into chromatin contribute to
define specific cellular identity and function. Dynamic regulation of chromatin organization …

Ovarian cancer (OC) is the fifth leading cause of women's death from cancers. The high
mortality rate is attributed to the late presence of the disease and the lack of modern …

Epigenetic research has rapidly evolved into a dynamic field of genome biology. Chromatin
regulation has been proved to be an essential aspect for all genomic processes, including …